Tianjin CanSino Biotechnology, a company focusing on human vaccines R&D, announced that they have started construction of an industry facility in the northeastern city of Tianjin to produce a China Ebola vaccine. The vaccine is developed jointly by the Bioengineering Institute of China’s Academy of Military Medical Sciences (AMMS) and Tianjin CanSino Biotechnology, and has moved onto a phase II clinical trial in Sierra Leone last Saturday. CanSino is planning to invest about $317 million into the facility and complete construction around 2017-2018.
Help employers find you! Check out all the jobs and post your resume.
